There is metabolic heterogeneity among individuals, and the metabolic heterogeneity of BCa may be driven by epigenetic regulation (such as m6A modification-regulating GLUT1 expression) or tumor stem cell characteristics. The gene discussed is SLC2A1; the disease is neoplasm.